Introduction
Inflammatory processes are thought to trigger prostate cancer (PCa) development and progression by causing dysregulation of oncogenes and tumour suppressors, thereby causing DNA damage and other processes which can induce tumour cell proliferation and growth. 1, 2 In keeping with this, men with intraprostatic conditions such as proliferative inflammatory atrophy, prostatic intraepithelial neoplasia and prostatitis, which may be driven by acute or chronic inflammation, are thought to be precursors of prostate cancer and, not surprisingly, have been associated with increased risk of this disease. 2, 3 Moreover, several environmental and biological factors including obesity, certain dietary practices, infectious agents and hormones, which can lead to increased or decreased production of circulating systemic inflammatory markers, such as CRP, have been implicated with PCa development and progression by promoting carcinogenic processes such as DNA damage and tumour cell growth and proliferation.
1,2 Furthermore, histological, genetic and animal studies have provided compelling evidence to suggest that chronic systemic inflammation may already be involved in the early prostate carcinogenic process. [4] [5] [6] In spite of these findings, there is a paucity of epidemiological studies on the role of markers of systemic inflammation such as albumin, haptoglobin, C-reactive protein (CRP) and white blood cell (WBC) levels in promoting PCa development and progression, and the evidence is inconclusive. While some studies demonstrate that CRP or WBC are associated with increased risk of incidental PCa or increased PCa mortality, [7] [8] [9] [10] other studies including one of our previous studies, involving a large cohort of men from Swedish Apolipoprotein-related, MORtality Risk study (AMORIS), have failed to provide evidence to support an association between inflammatory markers and risk of developing PCa. 1, [10] [11] [12] More studies on the potential association between systemic inflammation early in the natural history and PCa are, however, warranted to improve our understanding of how and when during the course of the disease systemic inflammation may be involved in driving the prostate carcinogenic process.
Given the lack of studies on inflammatory markers and PCa severity and progression, our study builds on our previous study by assessing the association between selected inflammatory markers and PCa incidence in the AMORIS cohort by further investigating the effect of inflammation on the disease severity and progression. Furthermore, to our knowledge, no other study has assessed how the timing of the inflammatory markers may influence prostate carcinogenesis. Thus, we specifically assessed how serum inflammatory markers (haptoglobin, albumin, CRP and WBC) measured early in the pre-clinical phase are associated with PCa severity (defined by PCa risk category and clinicopathological characteristics) among Swedish men. We also assessed the associations between the markers and progression (defined by PCa death).
Methods

Study design and population
The AMORIS study has been described in detail elsewhere. 13, 14 Briefly, this database includes 812,073 Swedish men and women with blood samples evaluated by the Central Automation Laboratory (CALAB) in Stockholm, Sweden, during the period 1985-1996. Individuals recruited were either healthy and having laboratory testing as part of a general check-up or outpatients referred for laboratory testing. None of the participants were inpatients at the time of sampling. 14 The CALAB database was linked to several Swedish national registries such as the Swedish National Cancer Register, the Hospital Discharge Register, the Cause of Death Register, the consecutive Swedish Censuses during , and the National Register of Emigration using the Swedish 10-digit personal identity number. [14] [15] [16] [17] For our study, we specifically focused on the linkage between the AMORIS database and the National Prostate Cancer Register (NPCR), which has been nationwide since 1998. 18 NPCR was developed to provide data for quality assurance and includes 98% of all newly diagnosed PCa cases registered in the Swedish National Cancer Register 18 to which reporting is mandated. From the NPCR, we extracted information on date of diagnosis, age at diagnosis, TNM stage, 18 Gleason score, serum concentration of PSA at time of diagnosis, and primary treatment given or planned up to 6 months after date of diagnosis. More specifically, we selected all men aged 30 and older with newly diagnosed PCa who had available information on their prostate tumour characteristics from 1996 until December 31, 2011, and had measurements of C-reactive protein (CRP), haptoglobin, albumin and white blood cell (WBC) taken about 13 years prior to their diagnosis (all four measurements were performed on the same day). This interval time was on average 13.8 years and ranged from 13 to 24 years. This time frame was chosen based on previous studies suggesting a lead time of 6-13 years as well as data availability in AMORIS. 19 A total of 8,471 men were included in the final analysis.
Exposure ascertainment and covariates
The primary exposures were serum levels of CRP, haptoglobin and albumin. High sensitivity CRP was not available during the period of blood sample collection (1985) (1986) (1987) (1988) (1989) (1990) (1991) (1992) (1993) (1994) (1995) (1996) . Therefore, CRP <10 mg/L could not be measured precisely. 20 However, the 10 mg/L cut-off has been widely accepted as the upper limit of the health associated reference range. 20 Albumin was measured using the bromocresol green method. Our analyses also included a subgroup of men with WBC measurements (n 5 2,057 . Using information from the National Patient Register, we calculated the Charlson Comorbidity Index which includes 19 diseases, with each disease category assigned a weight. These weights were then summed to create a score, resulting in four co-morbidity levels ranging from no co-morbidity to severe co-morbidity (0, 1, 2 and 3).
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Outcome ascertainment
Prostate cancer is a disease which is clinically and etiologically heterogeneous. 18 As we have previously investigated how these serum biomarkers are associated with overall risk of developing PCa, 12 our study focuses on disease severity at time of diagnosis (information which was previously not available in AMORIS), since this will allow us to take the heterogeneity of the disease into account. In addition, we assessed their role with PCa progression. The first will be defined using PCa risk categories and clinicopathological characteristics (i.e., PSA, Gleason score and T-category) whereas the latter will be defined by PCa-specific death. PCa risk category was defined in accordance with an adapted version of National Comprehensive Cancer Network as follows: low risk (T1-2, Gleason score 2-6 and PSA <10 ng/mL), intermediate risk (T1-2, Gleason score 7 and/or PSA 10 to <20 ng/mL), high risk (T3 and/or Gleason score 8-10 and/ or PSA 20 to <50 ng/mL) and regionally metastatic tumours (T4 and/or N1 and/or PSA 50 to <100 ng/mL in the absence of distant metastases (M0 or MX)) and distant metastatic tumours (M1 and/or PSA >100 ng/mL). 22 Other end points defining severity are PSA levels (median: 9.0 lg/L, interquartile range: 5.7-18.5), Gleason score and Tstage. PSA was categorised as <4 lg/L, 4-9.9 lg/L, 10-20 lg/L and >20 lg/L; Gleason score as 6, 3 1 4, 4 1 3 and 8, and T category as T1-T2 and T3-T4. Disease progression was defined as PCa death, which together with overall death was ascertained using the data obtained from the Cause of Death Register.
The study complied with the Declaration of Helsinki and was approved by the Ethics Review Board of the Karolinska Institute.
Statistical analysis
For our analyses, CRP, haptoglobin and WBC were categorised based on the clinical cut-offs used in the CALAB laboratory: CRP: <10 mg/L and 10 mg/L; haptoglobin: <1.4 g/L and 1.4 g/L; WBC <10 (10 9 L) and 10 (10 9 L). Albumin was dichotomised as <40 g/L and 40 g/L instead of the clinical cut-off of 35 g/L due to the small number of participants with low albumin levels. 23 Given the type of outcomes studied, our study used both logistic (i.e., PCa risk categories and characteristics) and Cox proportional hazards (i.e., PCa death) regression analyses. All covariates for the logistic and Cox regression models were selected a priori based on existing literature.
Odds ratios and 95% confidence intervals were calculated for the association of the serum inflammatory biomarkers with PCa risk categories and the PCa clinicopathological characteristics (PCa risk category, PSA levels, Gleason score, T category) using polytomous logistic regression. All exposures were modelled as both continuous and categorical variables. The continuous exposures were log-transformed as they were not normally distributed. In the multivariate models, we adjusted for age at diagnosis, education level (low, intermediate and high), CCI (0, 1, 2, 3) and interval time (continuous). A test for interaction between the exposures and interval time between date of measurement and date of diagnosis and prostate cancer risk categories was conducted by including an interaction term in the logistic models and testing its coefficient by the Wald test. We also performed stratified analyses based on time between date of serum measurement and date of PCa diagnosis to the analyses based on PCa risk category as an outcome.
Cox proportional hazard regression models were used to determine the hazard ratio (HR) and 95% CI for the association between the inflammatory markers and PCa death. Follow up time was determined as the time from PCa diagnosis until death from any cause, emigration or end of study (December 31, 2011), whichever occurred first. In addition to the covariates used in the multivariate logistic regression models, the Cox regression models were adjusted for PCa risk category (low risk, intermediate risk, high risk, regional/ distant metastatic). Schoenfeld residuals were assessed to test the proportional hazards assumption. There was no evidence of violation of the assumption.
A missing value indicator was included for all variables with missing information. We also performed sensitivity analyses among a sub-group of men with information on BMI to assess the confounding effect of BMI on the models. Data management and statistical analyses were performed with Statistical Analysis Software (SAS) release 9.3 (SAS Institute, Cary, NC).
Results
The median age at diagnosis for our study population was 68 (6 7.9) years (Table 1) . Most men had PSA levels of 4-10 lg/L; had Gleason score 6; had T1-T2 PCa and had low risk PCa. From a total of 1741 men who died, 779 died of PCa over a median follow-up time of 4.8 years (Table 1) .
CRP
After adjusting for age, educational level, CCI and interval time between date of measurement and date of diagnosis, men with high CRP levels (10 mg/L) had greater odds of high risk and regional/distant metastatic PCa compared to those with low CRP levels (<10 mg/L) (OR: 1.29; 95% CI: 1.07-1.56 and 1.32; 1.07-1.64, respectively) ( Table 2) . Similarly, men with high CRP levels had greater risk of having PCa with PSA levels of 10-19 mg/L and 20 mg/L (OR: 1.51; 95% CI: 1.27-1.79 and 1.50; 1.25-1.78, respectively) than those with lower CRP levels (Supporting Information Table  S1 ). Conversely, CRP levels were inversely associated with both Gleason score 3 1 4 and 4 1 3 tumours (OR: 0.82; 95% CI: 0.68-0.98 and 0.68; 0.53-0.87, respectively) (Supporting Information Table S1 ).
There was no association between CRP levels and Tcategory, PCa death or overall death (Table 3 and Supporting  Information Table S1 ).
Haptoglobin
After adjusting for potential confounders, men with high haptoglobin levels had increased odds of metastatic PCa (OR: 1.42; 95% CI: 1.14-1.77 and 1.51; 1.19-1.92 respectively); T3-T4 PCa (OR: 1.36; 95% CI: 1.14-1.63) and high PSA level (20 mg/L: OR: 1.45; 95% CI: 1.19-1.77) ( Fig. 1 and Supporting Information Table S1 ). Similar positive associations were observed when considering unit increase in log haptoglobin. There was also some suggestion of an increased risk of high grade PCa (8: OR: 1.25; 95% CI: 1.00-1.55) (Supporting Information Table S1 ), but no association was observed between haptoglobin and PCa death or overall death (Table 3) .
Albumin
In multivariate analyses, albumin levels were inversely associated with high risk and advanced PCa (adjusted OR: 0.71; Table S1 ). The inverse association between albumin and the aforementioned outcomes was also apparent when considering the continuous exposure ( Fig. 1 and Supporting Information Table S1 ). Having high albumin levels were, however, associated with increased risk of Gleason score 4 1 3 tumour (OR: 1.41; 95% CI: 1.04-1.90) (Supporting Information Table S1 ). There was also a suggestion of a positive association between albumin and overall death (HR per unit increase in log : 1.60; 95% CI: 1.11-2.30) ( Table 3) . Albumin was not associated with T3-T4 PCa, nor PCa death (Tables 3 and Supporting Information  Table S1 ).
WBC
Except for a positive association between WBC and T3-T4 PCa (OR per unit increase in log: 1.57; 95% CI: 1.03-2.38) (Supporting Information Table S1 ). There was no observed association between WBC levels and the remaining outcomes studied (Tables 2 and 3 , Fig. 1 and Supporting Information Fig. S1 ). 
Stratification by time since measurement
CRP Haptoglobin Albumin WBC <10 mg/L 10 mg/L <1.4 (g/L) 1.4 (g/L) <40 (g/L) 40 (g/L) <10
Sensitivity analyses
In analyses among a sub-group of men with information on BMI, the adjusting for BMI had virtually no effect on the models (Supporting Information Tables S2 and S3 ).
Discussion
Using serum measurements taken about 14 years prior to diagnosis, our study showed that men with higher CRP levels (10 mg/L) had greater odds of high risk or advanced PCa (regional/distant metastatic PCa); and PCa with PSA levels of 10-19 mg/L and 20 mg/L, but low risk of Gleason 3 1 4 and 4 1 3 tumours. Similarly, serum haptoglobin levels were positively associated with risk of advanced PCa (regional/distant metastatic PCa and T3-T4 PCa), high PSA level and possibly high grade PCa. While albumin was positively associated with Gleason 4 1 3 tumour, the associations with high risk and advanced PCa and higher PSA levels (10-19 mg/L and 20 mg/L) were inverse. There was, however, no evidence to suggest that serum CRP; haptoglobin or albumin levels were associated with PCa death or overall mortality. In addition, WBC was not associated with any of the outcomes studied. Although inflammation is a well-documented etiological factor in the development of cancer, very few studies have explored how CRP, a common clinical marker of inflammation, might be associated with PCa severity. Our findings suggest that high levels of this marker (10 mg/L) may be an important predictor of PCa severity. Supporting evidence from other studies showed that serum CRP levels was positively associated with advanced PCa and high PSA levels. 9, 24, 25 Interestingly, when exploring the association of CRP levels with the tumour grade, we observed an inverse association between high CRP levels and Gleason 3 1 4 and 4 1 3 tumours, but no associations were observed between CRP and high grade PCa. We did not find any other study which explored the association between CRP and PCa grade, but one previous study found that chronic inflammation was associated with high grade PCa; thus suggesting that inflammatory processes play an important role in tumour cell differentiation for higher grade tumours. 26 However, none of these previous studies provided detailed information on time between measurement and date of diagnosis, nor did they take into account this time in their analyses. Our stratified analyses further highlight the need to carefully assess the time between measurement and diagnosis, as Table 3 indicated that specifically those taken about 15 years or earlier were indicative of PCa severity. However, these findings will need to be confirmed in studies with repeated CRP measurements.
Although our study also failed to corroborate an association between CRP levels and PCa death, several studies including a recent meta-analysis reported that men with higher CRP levels at time of diagnosis had increased risk of PCa death. 7, 8, 27 Some genetic studies have also implicated certain CRP polymorphisms such as RNASEL with promoting PCa progression. 28, 29 Haptoglobin is another important systemic inflammatory marker which may be involved in the prostate carcinogenic pathway. Previously we reported a lack of association between haptoglobin and PCa incidence. 12 However, in our study, our findings imply that higher levels of haptoglobin may be associated with advanced disease (regional/distant metastatic PCa and T3-T4 PCa), PCa with high PSA levels and high grade PCa, but no associations were seen with PCa death or over death. Based on our findings, it appears that the association between haptoglobin and PCa varies by clinicopathological characteristics of the disease. However, to the best of our knowledge, except for grade of PCa, no previous epidemiological studies have been conducted to confirm this. 30 Similar to our study, Fujita et al. observed that elevated serum fucosylated haptoglobin level was associated with high grade PCa, but again the time between measurement and time of diagnosis was not defined. 30 Based on our stratified analyses, future studies should consider this timing more carefully as it suggests that measurements as early as 14-15 years prior to diagnosis may influence PCa severitywhich is important when further establishing the natural history of PCa. 31 The mechanism which underlies the potential association between haptoglobin and PCa carcinogenesis is also unknown. It is unclear if haptoglobin is a marker of an underlying promotive effect or a cancer promotor in itself. However, in some studies, haptoglobin polymorphisms have been positively associated with inflammation associated conditions such as atherosclerosis, autoimmune disorders and cancers such as breast cancer. 32 This may be partly explained by its role in facilitating oxidative stress and prostaglandin synthesis. 33 Haptoglobin may affect prostate carcinogenesis via similar processes, but further epidemiological and biological studies are needed to confirm its association with prostate carcinogenesis.
Hypoalbuminemia is a common occurrence in late stage cancer, partly resulting from the increased production of IL-6 and cytokines, which arises due to systemic inflammatory response to the tumour. 34 In this regard, we observed that albumin was inversely associated with high PSA levels and advanced PCa. Similar inverse associations have been reported by two earlier studies, which however did not provide any information about the timing of the measurements. 35, 36 In contrast, our study showed that albumin was positively associated with Gleason 4 1 3 tumours. No other study has investigated the association between albumin and 4 1 3 tumour, and therefore, this needs to be confirmed in future studies.
Serum albumin measured at time of diagnosis has also been shown to be an independent marker for overall cancer survival and survival from specific cancers such as colorectal and ovarian cancer. 37, 38 One previous study also found that men with hypoalbuminemia had greater risk of PCa mortality. 39 However, in our study, we did not find any evidence corroborating an association between albumin and overall or PCa survival. The lack of an association may be partly due to the relatively few events, and therefore, warrants further investigation in studies with larger sample size.
There is little epidemiological evidence to support an association between WBC and PCa outcomes. While we did not find any association between WBC and any of the outcomes, in one study, the monocyte fraction of WBCs was observed to be higher in men with high grade PCa. 40 Weak evidence from a Finnish study also reported a higher risk of PCa mortality among men with elevated leucocyte levels at time of diagnosis than men with normal leucocyte levels. 10 Despite the lack of an association between overall WBC levels and the outcomes studied, the importance of WBC in influencing PCa severity and progression cannot be negated, as increasing evidence has been suggesting that specific white blood cell components, such as neutrophils, and neutrophil to lymphocyte ratio may be important indicators of PCa severity and prognosis, [41] [42] [43] and should be further investigated. Despite the limited epidemiological evidence supporting an association between systemic inflammatory markers and PCa severity and progression, there is compelling biological evidence to corroborate an association between inflammatory processes and PCa. One study, for example, demonstrated that suppression of COX-2, an enzyme which triggers an increase in inflammatory responses, contributed to PCa cell cycle progression through inactivation of the EP1 receptor signalling and downregulation of kinetochore/centromere proteins. 44 Based on this premise, several studies have explored the link between aspirin, a COX inhibitor, and PCa outcomes. The findings, so far, remain inconclusive, [45] [46] [47] but several studies have reported an inverse association between aspirin use and metastatic PCa and PCa mortality. 45, 46 Animal models have also demonstrated that an intraprostatic inflammatory environment triggers alterations in the prostate epithelial cell microenvironment such as infiltration of immune cells, including B and T lymphocyte and activation of fibroblasts; thus already creating early-on an environment that is conducive to oxidative stress, genomic instability and other processes; thereby contributing to tumour cell growth and proliferation. 6, 48 Our study is one of the few studies to investigate the association between several commonly measured inflammatory markers and PCa severity and progression. Furthermore, all exposure measurements were taken from fresh blood samples, prior to diagnosis, at a central laboratory using an automated system. However, we only had single exposure measurements, which were mostly taken 14 years prior to PCa diagnosis -consistent with previous work looking into the potential time between exposure and diagnosis. 19 However, given the long natural history of PCa, it would be of interest to take the effect of longitudinal changes in these serum biomarkers into account. Future studies using repeated measurements are thus warranted -especially following the results of our time stratified analyses. Inflammation is a condition which is driven by multiple factors including lifestyle factors.
1 Except for BMI (only available for a small subgroup of men, we did not have information on lifestyle factors including physical activity and smoking which are known to influence inflammatory processes. 1 However, we aimed to take this potential confounding into account by using information on the Charlson Comorbidity Index as well as civil status and education. Moreover, we performed sensitivity analyses whereby we adjusted for BMI in the multivariate models. Adjusting did not materially change the estimates; thus suggesting that the observed associations were independent of obesity. Furthermore, these exposures are nonspecific systemic markers of inflammation. Hence, our study may not fully reflect the effect of inflammation on prostate carcinogenesis. We also had small number of events for some subgroups, and therefore had limited power to determine the true associations between the exposures and outcomes. Finally, our study population is based on a relatively healthy population with an all-cause mortality rate about 14% lower than in the general population of Stockholm county, 49 so that the findings may not be applicable to the general population. Nonetheless, it is unlikely that this had any effect on the internal validity of our study.
Conclusion
Our study corroborates a potential role for markers of systemic inflammation in the development of advanced PCa. In particular, higher serum CRP and haptoglobin levels were associated with PCa with high PSA levels and regional/distant metastatic disease, while the associations were inverse for hypoalbuminemia. Systemic inflammation as early as 14 years prior to diagnosis may influence PCa severity, raising the question whether the host environment influences progression to a more malignant phenotype -or helps select more malignant cell-clones -early in the natural history of the disease. To answer this question, future studies should take into consideration the timing of measurements to advance our understanding of the effect of inflammation over time on the natural history of the disease.
